Regarding the treatment of human pancreatic cancer, the team led by Mariafausta Fischietti identified SLFN5 as a pivotal regulator of cellular S-phase progression within the cell cycle through its binding/blocking of the transcriptional repressor E2F7, suggesting SLFN5 emerges as a promising novel therapeutic focus for pancreatic malignancies (33). This evidence concerns the gene SLFN5 and pancreatic neoplasm.